Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Rectal Cancer Patients × Clear all

Phase

Status

Not yet recruiting 3 Recruiting 2 Completed 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 375 Neoplasms 263 Carcinoma, Non-Small-Cell Lung 207 Prostatic Neoplasms 203 Colorectal Neoplasms 140 Lung Neoplasms 134 Pancreatic Neoplasms 121 Neoplasm Metastasis 120 Leukemia, Myeloid, Acute 119 Carcinoma, Hepatocellular 109 Multiple Myeloma 106 Lymphoma 98 Melanoma 91 Head and Neck Neoplasms 88 Ovarian Neoplasms 87 Brain Neoplasms 85 Recurrence 82 Leukemia, Lymphocytic, Chronic, B-Cell 77 Leukemia 77 Glioblastoma 73 Colonic Neoplasms 70 Squamous Cell Carcinoma of Head and Neck 67 Precursor Cell Lymphoblastic Leukemia-Lymphoma 67 Lymphoma, Non-Hodgkin 63 Carcinoma, Renal Cell 61 Lymphoma, Follicular 57 Hematologic Neoplasms 57 Lymphoma, Large B-Cell, Diffuse 56 Rectal Neoplasms 54 Stomach Neoplasms 50

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01426074 2018-08-21

DCE-MRI PET Bevacizumab Study in Rectal Cancer

Abramson Cancer Center at Penn Medicine

Phase 2 Withdrawn

Gastrointestinal

Rectal Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon ⚡